CG Oncology, Inc. Increase (Decrease) in Other Operating Assets
CG Oncology, Inc. (CGON) reported Increase (Decrease) in Other Operating Assets of $3.05 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInOtherOperatingAssets · last filed 2026-08-06
- CG Oncology, Inc. increase (decrease) in other operating assets for the quarter ending 2026-06-30 was $2.05M.
- CG Oncology, Inc. increase (decrease) in other operating assets for the quarter ending 2026-03-31 was $998.00K, a 2751.43% increase year-over-year.
- CG Oncology, Inc. increase (decrease) in other operating assets for the quarter ending 2025-12-31 was $1.56M, a 3714.63% increase year-over-year.
- CG Oncology, Inc. increase (decrease) in other operating assets for the quarter ending 2025-09-30 was $7.00K.
- CG Oncology, Inc. increase (decrease) in other operating assets for fiscal 2025 was $1.58M, a 2012.00% increase from fiscal 2024.
- CG Oncology, Inc. increase (decrease) in other operating assets for fiscal 2024 was $75.00K.
- CG Oncology, Inc. increase (decrease) in other operating assets for fiscal 2023 was -$13.00K.
| Period end | Increase (Decrease) in Other Operating Assets 3 month | Increase (Decrease) in Other Operating Assets 6 month | Increase (Decrease) in Other Operating Assets 9 month | Increase (Decrease) in Other Operating Assets 12 month |
|---|---|---|---|---|
| 2026-06-30 | $2.05M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $3.05M 10-Q · filed 2026-08-06 | $4.62M derived: sum of 3 quarters · filed 2026-08-06 | $4.62M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $998.00K 10-Q · filed 2026-05-08 | $2.56M derived: sum of 2 quarters · filed 2026-05-08 | $2.57M derived: sum of 3 quarters · filed 2026-05-08 | $2.55M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $1.56M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27 | $1.57M derived: sum of 2 quarters · filed 2026-02-27 | $1.55M derived: sum of 3 quarters · filed 2026-08-06 | $1.58M 10-K · filed 2026-02-27 |
| 2025-09-30 | $7.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | -$15.00K derived: sum of 2 quarters · filed 2026-08-06 | $20.00K 10-Q · filed 2025-11-14 | $61.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | -$22.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $13.00K 10-Q · filed 2026-08-06 | $54.00K derived: sum of 3 quarters · filed 2026-08-06 | $54.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $35.00K 10-Q · filed 2026-05-08 | $76.00K derived: sum of 2 quarters · filed 2026-05-08 | $76.00K derived: sum of 3 quarters · filed 2026-05-08 | $77.00K derived: sum of 4 quarters · filed 2026-05-08 |
| 2024-12-31 | $41.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27 | $41.00K derived: sum of 2 quarters · filed 2026-02-27 | $42.00K derived: sum of 3 quarters · filed 2026-02-27 | $75.00K 10-K · filed 2026-02-27 |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | $1.00K derived: sum of 2 quarters · filed 2025-11-14 | $34.00K 10-Q · filed 2025-11-14 | $34.00K derived: sum of 4 quarters · filed 2026-02-27 |
| 2024-06-30 | $1.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-08 | $34.00K 10-Q · filed 2025-08-08 | $34.00K derived: sum of 3 quarters · filed 2026-02-27 | |
| 2024-03-31 | $33.00K 10-Q · filed 2025-05-13 | $33.00K derived: sum of 2 quarters · filed 2026-02-27 | ||
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27 | -$13.00K 10-K · filed 2026-02-27 | ||
| 2023-09-30 | -$13.00K 10-Q · filed 2024-11-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 | |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| IOVANCE BIOTHERAPEUTICS, INC. (IOVA) | United States | $4.897B | -6.51 |
| Adaptive Biotechnologies Corp (ADPT) | United States | $4.719B | -53.43 |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |